PARP

December 7, 2018

OncLive’s State of the Science Summit Will Highlight Ovarian Cancer Treatments

News

OncLive’s latest State of the Science Summit will feature discussions of novel treatments for ovarian cancer and soft tissue sarcoma (STS), with presenters from the Dana-Farber Cancer Institute. To be ... Read more

February 26, 2018February 26, 2018

EMA’s CHMP Recommends Lynparza as Maintenance Therapy for Platinum-sensitive Ovarian Cancer

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that Lynparza (olaparib) be approved to prevent disease progression and relapse in ovarian cancer patients who responded to platinum-based ... Read more

August 19, 2017

Lynparza’s New Tablet Formulation Receives FDA Approval For Ovarian Cancer

News

A new formulation of Lynparza (olaparib) tablets received FDA approval to prevent disease progression and relapse in ovarian cancer patients. The new tablets allow patients previously taking the drug in capsule ... Read more